{"protocolSection": {"identificationModule": {"nctId": "NCT03756285", "orgStudyIdInfo": {"id": "D6580C00003"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.", "officialTitle": "A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre, Phase 2a Study to Assess Target Engagement, Safety and Tolerability of AZD4831 in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)", "acronym": "SATELLITE"}, "statusModule": {"statusVerifiedDate": "2021-06", "overallStatus": "TERMINATED", "whyStopped": "A decision was made to stop the study early when AstraZeneca evaluated the available data and it was considered that completing the study would provide limited additional information and unlikely to change the study conclusions.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-12-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-05-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-05-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-11-19", "studyFirstSubmitQcDate": "2018-11-26", "studyFirstPostDateStruct": {"date": "2018-11-28", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-05-07", "resultsFirstSubmitQcDate": "2021-06-29", "resultsFirstPostDateStruct": {"date": "2021-07-19", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-06-29", "lastUpdatePostDateStruct": {"date": "2021-07-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "A randomized, double-blind, placebo-controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will be conducted at approximately 15 sites in 5 countries. Approximately 96 patients will be randomized to AZD4831 or placebo (treatment duration 90 days).", "detailedDescription": "This is a randomized, double-blind, placebo controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and mid-range Ejection Fraction (HRmrEF). The study will be conducted at approximately 15 sites in 5 countries (USA, Sweden, Denmark, Finland, Netherlands). Patients suitable for the study will be checked for eligibility, signing the informed consent and enrolled to the study at visit 1. The study will be divided into two parts, Part A and Part B. In part A 37 patients will be randomized at visit 2 in a 2:1 ratio to once daily dosing of AZD4831 or matching placebo for approximately 90 days. After approximately 30 days of treatment, an interim analysis will be done to analyse the safety, tolerability and target engagement. After the evaluation, the randomization to Part B may proceed. In Part B the approximate 59 remaining patients will be randomized and treated for approximately 90 days."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Heart Failure with Ejection Fraction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 41, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "AZD4831", "type": "EXPERIMENTAL", "description": "AZD4831 tablets taken orally for for 90 days.", "interventionNames": ["Drug: AZD4831"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo tablets taken orally for 90 days.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "AZD4831", "description": "AZD4831 tablet taken orally for 90 days.", "armGroupLabels": ["AZD4831"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo tablet taken orally for 90 days.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in MPO Specific Activity", "description": "To compare the effect of AZD4831 to placebo on Target engagement, defined as ex vivo zymozan stimulated Myeloperoxidase (MPO) specific activity", "timeFrame": "Measurements on day 0, 10, 30 and 90. Change reported from day 0 to day 90."}], "secondaryOutcomes": [{"measure": "Change From Baseline in CFVR Measured in the Mid-distal Segment of the Left Anterior Descending (LAD) Coronary Artery Under Adenosine Infusion Measured by Transthoracic Doppler Echocardiography (TDE).", "description": "To compare the effect of AZD4831 to placebo on coronary flow velocity reserve (CFVR) measured in the mid-distal segment of the left anterior descending (LAD) coronary artery under adenosine infusion measured by Transthoracic Doppler Echocardiography (TDE).", "timeFrame": "Measurement on day 0 and 90."}, {"measure": "Change From Baseline in Walking Distance", "description": "To compare the effect of AZD4831 to placebo on 6 minutes walking test (6MWT)", "timeFrame": "Measurement on day 0, 30 and 90. Change reported from day 0 to day 90."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nInformed consent\n\n1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this CSP\n2. Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses\n\n   Age\n3. Patient must be 45 to 85 years of age inclusive, at the time of signing the informed consent form\n\n   Type of patient and disease characteristics\n4. Signs and symptoms of HF in judgement of Investigator AND\n\n   1. Stable NYHA II-IV and\n   2. Ejection fraction (EF) \u2265 40 % and\n   3. Elevated NT-proBNP or BNP in the last 1 year defined as:\n\n      o Measured as out-patient: NT-proBNP \u2265125 ng/L or BNP\u226535 ng/L with sinus rhythm, NT-proBNP \u2265750 ng/L or BNP \u2265200 ng/L with atrial fibrillation (AF),\n\n      or\n\n      o Measured when hospitalized acutely: NT-proBNP \u2265500 (ng/L) or BNP \u2265125 ng/L with sinus rhythm, NT-proBNP \u22651250 (ng/L) or BNP \u2265350 ng/L with AF\n   4. And at least one of the following:\n\n      * Hospitalization with HF as primary cause in last 12 months\n      * Structural heart disease on echo according to ESC guidelines i.e. either enlarged Left atrial volume index (LAVI \\> 34 ml/m2) or increased LVM (LVM index \\> 95 g/m2 in women and \\> 115 g/m2 in men)\n      * Pulmonary capillary wedge pressure (PCWP) at rest \\>15 mmHg or \\>25 mmHg at exercise\n      * Spectral tissue Doppler echocardiography - E/e' ratio \u226513 at rest\n\n   Weight\n5. Body Mass Index (BMI) range 18-40kg/m2\n\n   Sex\n6. Male or female of nonchildbearing potential\n\n   Reproduction\n7. Female patients must be 1 year post-menopausal or surgically sterile\n8. Male patients must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of AZD4831/matching placebo to prevent pregnancy in a partner. Male patients must not donate or bank sperm during this same time period\n\n   Genetic sampling\n9. For inclusion in this genetic research, patients must fulfil all of the inclusion criteria described above and provide informed consent for the genetic sampling and analysis\n\nExclusion Criteria:\n\nCreatinine clearance by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR \\<30 ml/min/1.73m2 or dialysis\n\nLife expectancy \\< 3 years due to other reasons than cardiovascular disease\n\nAny ongoing skin disorder, history of or ongoing clinically significant allergy/hypersensitivity.\n\nCurrent decompensated HF\n\nPrimary cardiomyopathy (e.g. constrictive, restrictive, infiltrative, toxic, hypertrophic, congenital or any primary cardiomyopathy) in judgment of investigator\n\nCurrent hemodynamically significant valve disease in opinion of investigator\n\nEF ever documented \\< 40%\n\nAny current life-threatening dysrhythmia\n\nProbable alternative primary reason for patient's symptoms in judgment of investigator, including but not limited to:\n\n1. Isolated pulmonary arterial hypertension or right ventricular (RV) failure; in the absence of left-sided HF\n2. Anaemia: Hb \\<100 mg/L (10g/dL)\n3. Severe chronic obstructive pulmonary disease (COPD) or lung disease (chronic O2, nebulizer or oral steroid therapy)\n\nCardiac surgery, acute coronary syndrome (ACS), or non-elective percutaneous coronary intervention (PCI) \\< 3 months\n\nKnown or clinically judged significant macrovascular coronary artery disease (CAD) that has not been revascularized\n\nHeart transplantation or left ventricular assist device ever\n\nPatients with uncontrolled or clinically significant thyroid disease as judged by the investigator.\n\nAlanine transaminase (ALT) or aspartate aminotransferase (AST) \u22652 x upper limit of normal (ULN). Resampling will not be allowed during the same screening period if detected abnormal values do not have reasonable explanation and are not expected to return to normal level within few days.\n\nKnown positive HIV, hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody, at screening", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "45 Years", "maximumAge": "85 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Research Site", "city": "Aarhus N", "zip": "8200", "country": "Denmark", "geoPoint": {"lat": 56.15674, "lon": 10.21076}}, {"facility": "Research Site", "city": "Herlev", "zip": "2730", "country": "Denmark", "geoPoint": {"lat": 55.72366, "lon": 12.43998}}, {"facility": "Research Site", "city": "Hvidovre", "zip": "2650", "country": "Denmark", "geoPoint": {"lat": 55.65719, "lon": 12.47364}}, {"facility": "Research Site", "city": "Odense C", "zip": "5000", "country": "Denmark", "geoPoint": {"lat": 55.39594, "lon": 10.38831}}, {"facility": "Research Site", "city": "Turku", "zip": "20520", "country": "Finland", "geoPoint": {"lat": 60.45148, "lon": 22.26869}}, {"facility": "Research Site", "city": "Deventer", "zip": "7416 SE", "country": "Netherlands", "geoPoint": {"lat": 52.255, "lon": 6.16389}}, {"facility": "Research Site", "city": "Dordrecht", "zip": "3318 AT", "country": "Netherlands", "geoPoint": {"lat": 51.81, "lon": 4.67361}}, {"facility": "Research Site", "city": "Groningen", "zip": "9713 GZ", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Research Site", "city": "G\u00f6teborg", "zip": "41345", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Research Site", "city": "Lund", "zip": "22242", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "Research Site", "city": "Stockholm", "zip": "171 76", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Redacted CSP", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6580C00003&amp;attachmentIdentifier=6f208598-cedf-467b-b3ef-41daf9951f1d&amp;fileName=D6580C00003_CSP_redacted.pdf&amp;versionIdentifier="}, {"label": "Redacted SAP", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6580C00003&amp;attachmentIdentifier=2ff3c524-3bff-46d8-b76d-c14d8c93cefd&amp;fileName=D6580C00003_SAP_redacted.pdf&amp;versionIdentifier="}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.\n\nYes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.", "infoTypes": ["STUDY_PROTOCOL", "SAP"], "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "accessCriteria": "When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "AZD4831", "description": "AZD4831 tablets taken orally for for 90 days."}, {"id": "FG001", "title": "Placebo", "description": "Placebo tablets taken orally for 90 days."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Study discontinued due to Other (Protocol deviation:subject meets exclusion criteria 20.)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Study discontinued due to Other (Dosing discontinued due to COVID-19)", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "AZD4831", "description": "AZD4831 tablets taken orally for for 90 days."}, {"id": "BG001", "title": "Placebo", "description": "Placebo tablets taken orally for 90 days."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "41"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "74.8", "spread": "6.61"}, {"groupId": "BG001", "value": "73.5", "spread": "6.99"}, {"groupId": "BG002", "value": "74.3", "spread": "6.68"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "19"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "22"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "41"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "40"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Country", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Denmark", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Netherlands", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}, {"title": "USA", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Finland", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "8"}]}, {"title": "Sweden", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "24"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in MPO Specific Activity", "description": "To compare the effect of AZD4831 to placebo on Target engagement, defined as ex vivo zymozan stimulated Myeloperoxidase (MPO) specific activity", "populationDescription": "20 of 27 patients in AZD4831 and 14 of 14 patients in placebo with evaluable measurements for analysis", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Measurements on day 0, 10, 30 and 90. Change reported from day 0 to day 90.", "groups": [{"id": "OG000", "title": "AZD4831", "description": "AZD4831 tablets taken orally for 90 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo tablets taken orally for 90 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.547", "lowerLimit": "0.379", "upperLimit": "0.790"}, {"groupId": "OG001", "value": "2.177", "lowerLimit": "1.168", "upperLimit": "4.058"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Covariates: atrial fibrillation status at randomization, baseline value, treatment, visit, and treatment\\*visit.", "paramType": "Least Square Means Ratio", "paramValue": "0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.12", "ciUpperLimit": "0.52"}]}, {"type": "SECONDARY", "title": "Change From Baseline in CFVR Measured in the Mid-distal Segment of the Left Anterior Descending (LAD) Coronary Artery Under Adenosine Infusion Measured by Transthoracic Doppler Echocardiography (TDE).", "description": "To compare the effect of AZD4831 to placebo on coronary flow velocity reserve (CFVR) measured in the mid-distal segment of the left anterior descending (LAD) coronary artery under adenosine infusion measured by Transthoracic Doppler Echocardiography (TDE).", "populationDescription": "18 of 27 patients in AZD4831 and 5 of 14 patients in placebo with evaluable measurements for analysis", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Measurement on day 0 and 90.", "groups": [{"id": "OG000", "title": "AZD4831", "description": "AZD4831 tablets taken orally for for 90 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo tablets taken orally for 90 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.975", "lowerLimit": "0.835", "upperLimit": "1.138"}, {"groupId": "OG001", "value": "1.002", "lowerLimit": "0.747", "upperLimit": "1.344"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.568", "statisticalMethod": "ANCOVA", "statisticalComment": "Covariates: atrial fibrillation status at randomization, baseline value, treatment", "paramType": "Least Square Means Ratio", "paramValue": "0.97", "ciPctValue": "95", "ciNumSides": "ONE_SIDED", "ciLowerLimit": "0.74"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Walking Distance", "description": "To compare the effect of AZD4831 to placebo on 6 minutes walking test (6MWT)", "populationDescription": "23 of 27 patients in AZD4831 and 11 of 14 patients in placebo with evaluable measurements for analysis", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Meters", "timeFrame": "Measurement on day 0, 30 and 90. Change reported from day 0 to day 90.", "groups": [{"id": "OG000", "title": "AZD4831", "description": "AZD4831 tablets taken orally for for 90 days."}, {"id": "OG001", "title": "Placebo", "description": "Placebo tablets taken orally for 90 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "47.4", "lowerLimit": "20.3", "upperLimit": "74.5"}, {"groupId": "OG001", "value": "25.6", "lowerLimit": "-19.8", "upperLimit": "71.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.407", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Covariates: atrial fibrillation status at randomization, baseline value, treatment, visit, and treatment\\*visit.", "paramType": "Mean Difference (Final Values)", "paramValue": "21.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.5", "ciUpperLimit": "74.1"}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "timeFrame": "Adverse Events will be collected from the time of the first dose throughout the treatment period and including the follow-up period, up to 124 days. Serious Adverse Events will be recorded from the time of signing the informed consent form through follow-up period, up to 124 days.", "eventGroups": [{"id": "EG000", "title": "AZD4831", "description": "AZD4831 tablets taken orally for for 90 days.", "deathsNumAffected": 0, "deathsNumAtRisk": 27, "seriousNumAffected": 2, "seriousNumAtRisk": 27, "otherNumAffected": 21, "otherNumAtRisk": 27}, {"id": "EG001", "title": "Placebo", "description": "Placebo tablets taken orally for 90 days.", "deathsNumAffected": 0, "deathsNumAtRisk": 14, "seriousNumAffected": 2, "seriousNumAtRisk": 14, "otherNumAffected": 9, "otherNumAtRisk": 14}], "seriousEvents": [{"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hospitalisation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}], "otherEvents": [{"term": "Gingivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Blindness", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Bleeding varicose vein", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Peripheral coldness", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dermatitis allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Musculoskeletal stiffness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Infusion site oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Blood urea increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Prostatic specific antigen increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Troponin T increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Scratch", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Subcutaneous haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Plicated tongue", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hospitalisation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA version 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Due to premature study termination, the statistical assumptions for the study design according to the Clinical Study Protocol could not be fulfilled, therefore, no statistical conclusions can be made based on primary or secondary efficacy objectives. Statistical significance could not be evaluated for any efficacy objectives and the p-values presented are viewed as nominal."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Global Clinical Lead", "organization": "AstraZeneca", "email": "information.center@astrazeneca.com", "phone": "1-877-240-9479"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-01-09", "uploadDate": "2021-05-07T04:40", "filename": "Prot_000.pdf", "size": 3259551}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-11-12", "uploadDate": "2021-05-07T04:40", "filename": "SAP_001.pdf", "size": 12908516}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-06-02", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}